{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:21:35Z","timestamp":1783642895705,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82200214"],"award-info":[{"award-number":["82200214"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hubei Provincial Natural Science Foundation and Xiangyang-of China","award":["2025AFD796"],"award-info":[{"award-number":["2025AFD796"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Diffuse large B-cell lymphoma (DLBCL) often resists therapy due to aberrant activation of NF-\u03baB signaling pathway. We synthesized and evaluated Z2-A-Z2, a novel organic arsenical, hypothesized to target this survival pathway, aiming to assess its efficacy and mechanism against DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      The novel compound Z2-A-Z2 was synthesized and verified by\n                      <jats:sup>1<\/jats:sup>\n                      H CMR,\n                      <jats:sup>13<\/jats:sup>\n                      C CMR, and high-resolution mass spectrometry. Its anti-proliferative activity was assessed in GCB- and ABC-subtype DLBCL cell lines and normal peripheral blood mononuclear cells (PBMCs) using CCK-8 assays. Mechanisms were elucidated through flow cytometry (apoptosis, ROS, \u0394\u03a8m), Western blot (apoptotic and NF-\u03baB pathway proteins), and enzyme activity assays. The causal role of ROS was confirmed by N-Acetylcysteine rescue (NAC) experiments, and the criticality of NF-\u03baB inhibition was validated using\n                      <jats:italic>p65<\/jats:italic>\n                      overexpression and pharmacological inhibition. Efficacy and safety were ultimately verified in SU-DHL-6 and U2932 xenograft model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Z2-A-Z2 demonstrated potent and selective anti-proliferative activity against DLBCL cell lines, achieving an average IC\u2085\u2080 of approximately 1.1 \u00b5M. This efficacy was 3- to 6-fold superior to arsenic trioxide (ATO), while exhibiting minimal cytotoxicity toward normal PBMCs and B cells. Mechanistically, Z2-A-Z2 induced profound mitochondrial-mediated apoptosis and G2\/M cell cycle arrest through a unique dual action of simultaneously triggering catastrophic oxidative stress and critically suppressing the pro-survival NF-\u03baB\/I\u03baB\u03b1 signaling axis. Further investigation revealed a bidirectional regulation where ROS acts upstream to suppress p65 activity, while p65 in turn modulates drug-induced ROS generation. In vivo studies further validated these findings, showing that Z2-A-Z2 resulted in a robust suppression of tumor growth in a xenograft model, accompanied by diminished NF-\u03baB\/I\u03baB\u03b1 activity and increased apoptosis, alongside an excellent safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Z2-A-Z2 is a promising organic arsenical with superior efficacy and safety over ATO. Its unique dual-action strategy of simultaneously inducing oxidative stress and critically inhibiting the NF-\u03baB\/I\u03baB\u03b1 signaling axis, positioning it as a strong clinical candidate for effectively treating DLBCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03724-4","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:12:06Z","timestamp":1779109926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Superior anti-DLBCL efficacy of novel organic arsenical Z2-A-Z2 through ROS-mediated apoptosis and critical NF-\u03baB\/I\u03baB\u03b1 signaling pathway inhibition"],"prefix":"10.1186","volume":"45","author":[{"given":"Wenjiao","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanni","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangnian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"9","key":"3724_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Longo DL, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842\u201358.","journal-title":"N Engl J Med"},{"key":"3724_CR2","doi-asserted-by":"crossref","unstructured":"Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer treatment reviews. 2022;110:102443.","DOI":"10.1016\/j.ctrv.2022.102443"},{"key":"3724_CR3","doi-asserted-by":"crossref","unstructured":"Shumilov E, Boyadzhiev H, Mazzeo P, Akhoundova D, Daskalakis M, Novak U, et al. CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement. HemaSphere. 2023;7(12):e984.","DOI":"10.1097\/HS9.0000000000000984"},{"issue":"12","key":"3724_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1182\/blood.2023020197","volume":"142","author":"D Chihara","year":"2023","unstructured":"Chihara D, Liao L, Tkacz J, Franco A, Lewing B, Kilgore KM, et al. Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2023;142(12):1047\u201355.","journal-title":"Blood"},{"issue":"20","key":"3724_CR5","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-14-0497","volume":"20","author":"K Dunleavy","year":"2014","unstructured":"Dunleavy K, Roschewski M, Wilson WH. Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype. Clin Cancer Res. 2014;20(20):5182\u201393.","journal-title":"Clin Cancer Res"},{"issue":"7247","key":"3724_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717\u201321.","journal-title":"Nature"},{"issue":"8","key":"3724_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41423-025-01310-w","volume":"22","author":"H Mao","year":"2025","unstructured":"Mao H, Zhao X, Sun S-c. NF-\u03baB in inflammation and cancer. Cell Mol Immunol. 2025;22(8):811\u201339.","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"3724_CR8","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.18632\/aging.101121","volume":"8","author":"M Zhang","year":"2016","unstructured":"Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, et al. RelA NF-\u03baB subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging. 2016;8(12):3321\u201340.","journal-title":"Aging"},{"key":"3724_CR9","doi-asserted-by":"publisher","first-page":"155747","DOI":"10.1016\/j.metabol.2023.155747","volume":"151","author":"R Shah","year":"2024","unstructured":"Shah R, Ibis B, Kashyap M, Boussiotis VA. The role of ROS in tumor infiltrating immune cells and cancer immunotherapy. Metabolism. 2024;151:155747.","journal-title":"Metabolism"},{"issue":"8","key":"3724_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","volume":"23","author":"C Glorieux","year":"2024","unstructured":"Glorieux C, Liu S, Trachootham D, Huang P. Targeting ROS in cancer: rationale and strategies. Nat Rev Drug Discov. 2024;23(8):583\u2013606.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3724_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2010.04.020","volume":"297","author":"HL Tian","year":"2010","unstructured":"Tian HL, Yu T, Xu NN, Feng C, Zhou LY, Luo HW, et al. A novel compound modified from tanshinone inhibits tumor growth in vivo via activation of the intrinsic apoptotic pathway. Cancer Lett. 2010;297(1):18\u201330.","journal-title":"Cancer Lett"},{"key":"3724_CR12","doi-asserted-by":"publisher","first-page":"102754","DOI":"10.1016\/j.redox.2023.102754","volume":"63","author":"H Jiang","year":"2023","unstructured":"Jiang H, Zuo J, Li B, Chen R, Luo K, Xiang X, et al. Drug-induced oxidative stress in cancer treatments: Angel or devil? Redox Biol. 2023;63:102754.","journal-title":"Redox Biol"},{"issue":"1","key":"3724_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41423-022-00956-0","volume":"20","author":"J Chen","year":"2022","unstructured":"Chen J, Jin Z, Zhang S, Zhang X, Li P, Yang H, et al. Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. Cell Mol Immunol. 2022;20(1):51\u201364.","journal-title":"Cell Mol Immunol"},{"issue":"24","key":"3724_CR14","doi-asserted-by":"publisher","first-page":"7433","DOI":"10.1182\/bloodadvances.2023010964","volume":"7","author":"B Gomez Solsona","year":"2023","unstructured":"Gomez Solsona B, Horn H, Schmitt A, Xu W, Bucher P, Heinrich A, et al. Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress. Blood Adv. 2023;7(24):7433\u201344.","journal-title":"Blood Adv"},{"issue":"1","key":"3724_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1756-9966-33-42","volume":"33","author":"S Kumar","year":"2014","unstructured":"Kumar S, Yedjou CG, Tchounwou PB. Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells. J Exp Clin Cancer Res. 2014;33(1):42.","journal-title":"J Exp Clin Cancer Res"},{"issue":"33","key":"3724_CR16","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1200\/JCO.2013.51.2913","volume":"32","author":"GJ Roboz","year":"2014","unstructured":"Roboz GJ, Ritchie EK, Carlin RF, Samuel M, Gale L, Provenzano-Gober JL, et al. Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic Trioxide. J Clin Oncol. 2014;32(33):3723\u20138.","journal-title":"J Clin Oncol"},{"key":"3724_CR17","doi-asserted-by":"crossref","unstructured":"Yan M, Wang H, Wei R, Li W. Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date. Archives of pharmacal research. 2024;47(3):249-71.","DOI":"10.1007\/s12272-023-01481-y"},{"key":"3724_CR18","doi-asserted-by":"crossref","unstructured":"Liu Y, She W, Li Y, Wang M, Liu Y, Ning B, et al. Aa-Z2 triggers ROS-induced apoptosis of osteosarcoma by targeting PDK-1. J Transl Med. 2023;21(1):7.","DOI":"10.1186\/s12967-022-03862-1"},{"key":"3724_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.freeradbiomed.2019.11.013","volume":"146","author":"D Zhang","year":"2020","unstructured":"Zhang D, Liu Y, Luo Z, Chen Y, Xu A, Liang Y, et al. The novel thioredoxin reductase inhibitor A-Z2 triggers intrinsic apoptosis and shows efficacy in the treatment of acute myeloid leukemia. Free Radic Biol Med. 2020;146:275\u201386.","journal-title":"Free Radic Biol Med"},{"issue":"50","key":"3724_CR20","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.1038\/onc.2013.565","volume":"33","author":"D Nagel","year":"2014","unstructured":"Nagel D, Vincendeau M, Eitelhuber AC, Krappmann D. Mechanisms and consequences of constitutive NF-\u03baB activation in B-cell lymphoid malignancies. Oncogene. 2014;33(50):5655\u201365.","journal-title":"Oncogene"},{"issue":"1","key":"3724_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cr.2010.178","volume":"21","author":"MJ Morgan","year":"2010","unstructured":"Morgan MJ, Liu Z-g. Crosstalk of reactive oxygen species and NF-\u03baB signaling. Cell Res. 2010;21(1):103\u201315.","journal-title":"Cell Res"},{"issue":"2","key":"3724_CR22","doi-asserted-by":"publisher","first-page":"119573","DOI":"10.1016\/j.bbamcr.2023.119573","volume":"1871","author":"D Averill-Bates","year":"2024","unstructured":"Averill-Bates D. Reactive oxygen species and cell signaling. Rev Biochim Biophys Acta Mol Cell Res. 2024;1871(2):119573.","journal-title":"Rev Biochim Biophys Acta Mol Cell Res"},{"issue":"10","key":"3724_CR23","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1007\/s00204-023-03562-9","volume":"97","author":"K Jomova","year":"2023","unstructured":"Jomova K, Raptova R, Alomar SY, Alwasel SH, Nepovimova E, Kuca K, et al. Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging. Arch Toxicol. 2023;97(10):2499\u2013574.","journal-title":"Arch Toxicol"},{"issue":"Pt 2","key":"3724_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1042\/bj3520583","volume":"352","author":"C Glineur","year":"2000","unstructured":"Glineur C, Davioud-Charvet E, Vandenbunder B. The conserved redox-sensitive cysteine residue of the DNA-binding region in the c-Rel protein is involved in the regulation of the phosphorylation of the protein. Biochem J. 2000;352(Pt 2):583\u201391.","journal-title":"Biochem J"},{"issue":"24","key":"3724_CR25","doi-asserted-by":"publisher","first-page":"8945","DOI":"10.1073\/pnas.0400588101","volume":"101","author":"NL Reynaert","year":"2004","unstructured":"Reynaert NL, Ckless K, Korn SH, Vos N, Guala AS, Wouters EF, et al. Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci USA. 2004;101(24):8945\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3724_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13046-018-1005-y","volume":"37","author":"Y Qiu","year":"2018","unstructured":"Qiu Y, Dai Y, Zhang C, Yang Y, Jin M, Shan W, et al. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3\u03b7\/NF-\u03baB feedback loop. J experimental Clin cancer research: CR. 2018;37(1):321.","journal-title":"J experimental Clin cancer research: CR"},{"issue":"18","key":"3724_CR27","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","volume":"19","author":"SL Soignet","year":"2001","unstructured":"Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19(18):3852\u201360.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03724-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03724-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03724-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:04:26Z","timestamp":1783641866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03724-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3724"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03724-4","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics and Scientific Committee of the Hubei University of Medicine (approval number XYYYE20240074).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}